Skip to main content
SpringerLink
Log in

Paraneoplastic Neurologic Disease

  • Chapter
  • First Online:
Neurorheumatology

  • 997 Accesses

Abstract

Paraneoplastic neurologic disease (PND) is characterized by an aberrant immune-mediated response against the nervous system in the context of an underlying malignancy. Certain malignancies are more notorious for being associated with PND than others, including small cell lung cancer and neuroblastoma (neuroendocrine proteins), teratomas (neuronal components), thymomas (immunoregulatory system), and lymphoma or myeloma (antibody production). The clinical severity of paraneoplastic syndromes can range from mild to catastrophic, with significant heterogeneity possible even among a particular antibody.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Pittock SJ, Vincent A. Introduction to autoimmune neurology. Handb Clin Neurol. 2016;133:3–14.

    Article  PubMed  Google Scholar 

  2. Pittock SJ, Vincent A. Introduction to autoimmune neurology. Handb Clin Neurol. 2016;133:3–14.

    Google Scholar 

  3. Lancaster E, Dalmau J. Neuronal autoantigens – pathogenesis, associated disorders and antibody testing. Nat Rev Neurol. 2012;8(7):380–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Pittock SJ, Palace J. Paraneoplastic and idiopathic autoimmune neurologic disorders: approach to diagnosis and treatment. Handb Clin Neurol. 2016;133:165–83.

    Article  PubMed  Google Scholar 

  5. Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol. 2004;56(5):715–9.

    Article  CAS  PubMed  Google Scholar 

  6. Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008;7(4):327–40.

    Article  PubMed  PubMed Central  Google Scholar 

  7. McKeon A, Apiwattanakul M, Lachance DH, Lennon VA, Mandrekar JN, Boeve BF, et al. Positron emission tomography-computed tomography in paraneoplastic neurologic disorders: systematic analysis and review. Arch Neurol. 2010;67(3):322–9.

    Article  PubMed  Google Scholar 

  8. Graus F, Cordon-Cardo C, Posner JB. Neuronal antinuclear antibody in sensory neuronopathy from lung cancer. Neurology. 1985;35(4):538–43.

    Article  CAS  PubMed  Google Scholar 

  9. Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology. 1998;50(3):652–7.

    Article  CAS  PubMed  Google Scholar 

  10. Graus F, Keime-Guibert F, Rene R, Benyahia B, Ribalta T, Ascaso C, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain J Neurol. 2001;124(Pt 6):1138–48.

    Article  CAS  Google Scholar 

  11. Sillevis Smitt P, Grefkens J, de Leeuw B, van den Bent M, van Putten W, Hooijkaas H, et al. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol. D - 0423161. 2002;249(6):745–753.

    Article  PubMed  Google Scholar 

  12. Luque FA, Furneaux HM, Ferziger R, Rosenblum MK, Wray SH, Schold SC Jr, et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol. 1991;29(3):241–51.

    Article  CAS  PubMed  Google Scholar 

  13. Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol. 2003;53(5):580–7.

    Article  CAS  PubMed  Google Scholar 

  14. Dropcho EJ, Kline LB, Riser J. Antineuronal (anti-Ri) antibodies in a patient with steroid-responsive opsoclonus-myoclonus. Neurology. 1993;43(1):207–11.

    Article  CAS  PubMed  Google Scholar 

  15. Chan KH, Vernino S, Lennon VA. ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol. 2001;50(3):301–11.

    Article  CAS  PubMed  Google Scholar 

  16. Bataller L, Wade DF, Graus F, Stacey HD, Rosenfeld MR, Dalmau J. Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology. 2004;62(5):778–82.

    Article  CAS  PubMed  Google Scholar 

  17. Dalmau J, Graus F, Villarejo A, Posner JB, Blumenthal D, Thiessen B, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain. 2004;127:1831–44.

    Article  PubMed  Google Scholar 

  18. Overeem S, Dalmau J, Bataller L, Nishino S, Mignot E, Verschuuren J, et al. Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis. Neurology. 2004;62(1):138–40.

    Article  CAS  PubMed  Google Scholar 

  19. Schuller M, Jenne D, Voltz R. The human PNMA family: novel neuronal proteins implicated in paraneoplastic neurological disease. J Neuroimmunol. 2005;169:172–6.

    Article  PubMed  CAS  Google Scholar 

  20. Dalmau J, Gultekin SH, Voltz R, Hoard R, DesChamps T, Balmaceda C, et al. Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain J Neurol. 1999;122(Pt 1):27–39.

    Article  Google Scholar 

  21. Sabater L, Titulaer M, Saiz A, Verschuuren J, Gure AO, Graus F. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology. 2008;70(12):924–8.

    Article  CAS  PubMed  Google Scholar 

  22. Folli F, Solimena M, Cofiell R, Austoni M, Tallini G, Fassetta G, et al. Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med. 1993;328(8):546–51.

    Article  CAS  PubMed  Google Scholar 

  23. Pittock SJ, Lucchinetti CF, Parisi JE, Benarroch EE, Mokri B, Stephan CL, et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol. 2005;58(1):96–107.

    Article  PubMed  Google Scholar 

  24. Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol. 2001;49(2):146–54.

    Article  CAS  PubMed  Google Scholar 

  25. Vernino S, Tuite P, Adler CH, Meschia JF, Boeve BF, Boasberg P, et al. Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol. 2002;51(5):625–30.

    Article  PubMed  Google Scholar 

  26. Cross SA, Salomao DR, Parisi JE, Kryzer TJ, Bradley EA, Mines JA, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol. 2003;54(1):38–50.

    Article  PubMed  Google Scholar 

  27. Pulido J, Cross SA, Lennon VA, Pulido J, Swanson D, Muench M, et al. Bilateral autoimmune optic neuritis and vitreitis related to CRMP-5-IgG: intravitreal triamcinolone acetonide therapy of four eyes. Eye (Lond). 2008;22(9):1191–3.

    Article  CAS  Google Scholar 

  28. Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology. 1992;42(10):1931–7.

    Article  CAS  PubMed  Google Scholar 

  29. Hetzel DJ, Stanhope CR, O’Neill BP, Lennon VA. Gynecologic cancer in patients with subacute cerebellar degeneration predicted by anti-Purkinje cell antibodies and limited in metastatic volume. Mayo Clin Proc. 1990;65(12):1558–63.

    Article  CAS  PubMed  Google Scholar 

  30. Shams’ili S, Grefkens J, de Leeuw B, van den Bent M, Hooijkaas H, van der Holt B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain J Neurol. 2003;126(Pt 6):1409–18.

    Article  Google Scholar 

  31. McKeon A, Pittock SJ. Paraneoplastic encephalomyelopathies: pathology and mechanisms. Acta Neuropathol. 2011;122(4):381–400.

    Article  CAS  PubMed  Google Scholar 

  32. Jones AL, Flanagan EP, Pittock SJ, Mandrekar JN, Eggers SD, Ahlskog JE, et al. Responses to and outcomes of treatment of autoimmune cerebellar ataxia in adults. JAMA Neurol. 2015;72(11):1304–12.

    Article  PubMed  Google Scholar 

  33. Vernino S, Lennon VA. New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol. 2000;47(3):297–305.

    Article  CAS  PubMed  Google Scholar 

  34. Thirkill CE, FitzGerald P, Sergott RC, Roth AM, Tyler NK, Keltner JL. Cancer-associated retinopathy (CAR syndrome) with antibodies reacting with retinal, optic-nerve, and cancer cells. N Engl J Med. 1989;321(23):1589–94.

    Article  CAS  PubMed  Google Scholar 

  35. Guy J, Aptsiauri N. Treatment of paraneoplastic visual loss with intravenous immunoglobulin: report of 3 cases. Arch Ophthalmol. 1999;117(4):471–7.

    Article  CAS  PubMed  Google Scholar 

  36. Silverman IE. Paraneoplastic stiff limb syndrome. J Neurol Neurosurg Psychiatry. [Comment Letter]. 1999;67(1):126–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Sinnreich M, Assal F, Hefft S, Magistris MR, Chizzolini C, Landis T, et al. Anti-gad antibodies and breast cancer in a patient with stiff-person syndrome: a puzzling association. Eur Neurol. [Case Reports]. 2001;46(1):51–2.

    Article  CAS  PubMed  Google Scholar 

  38. Vernino S, Lennon VA. Autoantibody profiles and neurological correlations of thymoma. Clin Cancer Res. 2004;10(21):7270–5.

    Article  CAS  PubMed  Google Scholar 

  39. Pittock SJ, Yoshikawa H, Ahlskog JE, Tisch SH, Benarroch EE, Kryzer TJ, et al. Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc. 2006;81(9):1207–14.

    Article  CAS  PubMed  Google Scholar 

  40. Saiz A, Bruna J, Stourac P, Vigliani MC, Giometto B, Grisold W, et al. Anti-Hu-associated brainstem encephalitis. J Neurol Neurosurg Psychiatry. [Research Support, Non-US Gov’t]. 2009;80(4):404–7.

    Article  CAS  Google Scholar 

  41. Agarwal PA, Ichaporia NR. Glutamic acid decarboxylase antibody-positive paraneoplastic stiff limb syndrome associated with carcinoma of the breast. Neurol India. [Case Reports]. 2010;58(3):449–51.

    Article  Google Scholar 

  42. Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol. 2010;67(4):470–8.

    Article  PubMed  Google Scholar 

  43. Arino H, Gresa-Arribas N, Blanco Y, Martinez-Hernandez E, Sabater L, Petit-Pedrol M, et al. Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy. JAMA neurology. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. 2014;71(8):1009–16.

    Google Scholar 

  44. Fang B, McKeon A, Hinson SR, Kryzer TJ, Pittock SJ, Aksamit AJ, et al. Autoimmune glial fibrillary acidic protein astrocytopathy: a novel meningoencephalomyelitis. JAMA Neurol. 2016;73(11):1297–307.

    Article  PubMed  Google Scholar 

  45. Rozelle A, Trieu S, Chung L. Malignancy in the setting of the anti-synthetase syndrome. J Clin Rheumatol. 2008;14(5):285–8.

    Article  PubMed  Google Scholar 

  46. Mileti LM, Strek ME, Niewold TB, Curran JJ, Sweiss NJ. Clinical characteristics of patients with anti-Jo-1 antibodies: a single center experience. J Clin Rheumatol. 2009;15(5):254–5.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Marie I. Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep. 2012;14(3):275–85.

    Article  CAS  PubMed  Google Scholar 

  48. Kassardjian CD, Lennon VA, Alfugham NB, Mahler M, Milone M. Clinical features and treatment outcomes of necrotizing autoimmune myopathy. JAMA Neurol. 2015;72(9):996–1003.

    Article  PubMed  Google Scholar 

  49. Thieben MJ, Lennon VA, Boeve BF, Aksamit AJ, Keegan M, Vernino S. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology. 2004;62:1177–82.

    Article  CAS  PubMed  Google Scholar 

  50. Pozo-Rosich P, Clover L, Saiz A, Vincent A, Graus F. Voltage-gated potassium channel antibodies in limbic encephalitis. Ann Neurol. 2003;54(4):530–3.

    Article  CAS  PubMed  Google Scholar 

  51. Vincent A, Buckley C, Schott JM, Baker I, Dewar BK, Detert N, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain J Neurol. 2004;127(Pt 3):701–12.

    Article  Google Scholar 

  52. Klein CJ, Lennon VA, Aston PA, McKeon A, Pittock SJ. Chronic pain as a manifestation of potassium channel-complex autoimmunity. Neurology. 2012;79(11):1136–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Lai M, Huijbers MG, Lancaster E, Graus F, Bataller L, Balice-Gordon R, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 2010;9(8):776–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, et al. Antibodies to kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, morvan’s syndrome and acquired neuromyotonia. Brain J Neurol. 2010;133(9):2734–48.

    Article  Google Scholar 

  55. Navarro V, Kas A, Apartis E, Chami L, Rogemond V, Levy P, et al. Motor cortex and hippocampus are the two main cortical targets in LGI1-antibody encephalitis. Brain J Neurol. 2016;139(Pt 4):1079–93.

    Article  Google Scholar 

  56. van Sonderen A, Arino H, Petit-Pedrol M, Leypoldt F, Kortvelyessy P, Wandinger KP, et al. The clinical spectrum of Caspr2 antibody-associated disease. Neurology. 2016;87(5):521–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  57. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10(1):63–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Pruss H, Holtje M, Maier N, Gomez A, Buchert R, Harms L, et al. IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment. Neurology. 2012;78:1743–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Titulaer MJ, McCracken L, Gabilondo I, Armangue T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Lai M, Hughes EG, Peng X, Zhou L, Gleichman AJ, Shu H, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol. 2009;65(4):424–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Hoftberger R, van Sonderen A, Leypoldt F, Houghton D, Geschwind M, Gelfand J, et al. Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients. Neurology. 2015;84(24):2403–12.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  62. Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J, et al. Antibodies to the GABA(b) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol. 2010;9(1):67–76.

    Article  CAS  PubMed  Google Scholar 

  63. Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology. 2011;77(2):179–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Hoftberger R, Titulaer MJ, Sabater L, Dome B, Rozsas A, Hegedus B, et al. Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology. 2013;81(17):1500–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  65. Petit-Pedrol M, Armangue T, Peng X, Bataller L, Cellucci T, Davis R, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol. 2014;13(3):276–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Lennon VA. Calcium channel and related paraneoplastic disease autoantibodies. In: Peter JB, Schoenfeld Y, editors. Textbook of autoantibodies. Amsterdam: Elsevier Science Publishers, B.V.; 1996. p. 139–47.

    Chapter  Google Scholar 

  67. Harper CM, Lennon VA. Lambert-Eaton syndrome. In: Kaminski HJ, editor. Current clinical neurology: myasthenia gravis and related disorders. Totowa: Humana Press; 2003. p. 269–91.

    Chapter  Google Scholar 

  68. Lennon VA, Kryzer TJ, Griesmann GE, O’Suilleabhain PE, Windebank AJ, Woppmann A, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med. 1995;332(22):1467–74.

    Article  CAS  PubMed  Google Scholar 

  69. Bain PG, Motomura M, Newsom-Davis J, Misbah SA, Chapel HM, Lee ML, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology. 1996;47(3):678–83.

    Article  CAS  PubMed  Google Scholar 

  70. Zalewski NL, Lennon VA, Lachance DH, Klein CJ, Pittock SJ, McKeon A. P/Q- and N-type calcium-channel antibodies: oncological, neurological, and serological accompaniments. Muscle Nerve. 2016;54(2):220–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Flanagan EP, Cabre P, Weinshenker BG, St Sauver J, Jacobson DJ, Majed M, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol. 2016;79(5):775–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Vernino S, Low PA, Fealey RD, Stewart JD, Farrugia G, Lennon VA. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med. 2000;343(12):847–55.

    Article  CAS  PubMed  Google Scholar 

  74. Lennon VA, Ermilov LG, Szurszewski JH, Vernino S. Immunization with neuronal nicotinic acetylcholine receptor induces neurological autoimmune disease. J Clin Invest. 2003;111(6):907–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Vernino S, Ermilov LG, Sha L, Szurszewski JH, Low PA, Lennon VA. Passive transfer of autoimmune autonomic neuropathy to mice. J Neurosci. 2004;24(32):7037–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. McKeon A, Lennon VA, Lachance DH, Fealey RD, Pittock SJ. Ganglionic acetylcholine receptor autoantibody: oncological, neurological, and serological accompaniments. Arch Neurol. 2009;66(6):735–41.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Lennon VA. Serological profile of myasthenia gravis and distinction from the Lambert-Eaton myasthenic syndrome. Neurology. 1997;48(Suppl. 5):S23–7.

    Article  Google Scholar 

  78. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. (original article: Lindstrom J, Seybold ME, Lennon VA, Whittingham S and Duane DD. (1976). Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. Neurology 26:1054–1059). Neurology. 1998;51(4):933.

    PubMed  Google Scholar 

  79. Lennon VA, Lindstrom JM, Seybold ME. Experimental autoimmune myasthenia gravis: cellular and humoral immune responses. Ann N Y Acad Sci. 1976;274:283–99.

    Article  CAS  PubMed  Google Scholar 

  80. Drachman DB. Myasthenia gravis. N Engl J Med. 1994;330(25):1797–810.

    Article  CAS  PubMed  Google Scholar 

  81. Mao ZF, Mo XA, Qin C, Lai YR, Hackett ML. Incidence of thymoma in myasthenia gravis: a systematic review. J Clin Neurol (Seoul, Korea.). 2012;8(3):161–9.

    Article  Google Scholar 

  82. McKeon A, Martinez-Hernandez E, Lancaster E, Matsumoto JY, Harvey RJ, McEvoy KM, et al. Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. Arch Neurol. 2012;22:1–9.

    Google Scholar 

  83. Hutchinson M, Waters P, McHugh J, Gorman G, O’Riordan S, Connolly S, et al. Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology. 2008;71(16):1291–2.

    Article  CAS  PubMed  Google Scholar 

  84. Sillevis-Smitt P, Kinoshita A, De Leeuw B, Moll W, Coesmans M, Jaarsma D, et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med. 2000;342(1):21–7.

    Article  CAS  PubMed  Google Scholar 

  85. Pruss H, Rothkirch M, Kopp U, Hamer HM, Hagge M, Sterzer P, et al. Limbic encephalitis with mGluR5 antibodies and immunotherapy-responsive prosopagnosia. Neurology. 2014;83(15):1384–6.

    Article  PubMed  Google Scholar 

  86. Lancaster E, Martinez-Hernandez E, Titulaer MJ, Boulos M, Weaver S, Antoine JC, et al. Antibodies to metabotropic glutamate receptor 5 in the ophelia syndrome. Neurology. 2011;77(18):1698–701.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Boronat A, Gelfand JM, Gresa-Arribas N, Jeong HY, Walsh M, Roberts K, et al. Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of kv4.2 potassium channels. Ann Neurol. 2013;73(1):120–8.

    Article  CAS  PubMed  Google Scholar 

  88. Tobin WO, Lennon VA, Komorowski L, Probst C, Clardy SL, Aksamit AJ, et al. DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology. 2014;83(20):1797–803.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Bernal F, Shams’ili S, Rojas I, Sanchez-Valle R, Saiz A, Dalmau J, et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and hodgkin’s disease. Neurology. 2003;60(2):230–4.

    Article  CAS  PubMed  Google Scholar 

  90. Trotter JL, Hendin BA, Osterland CK. Cerebellar degeneration with hodgkin disease. An immunological study. Arch Neurol. 1976;33(9):660–1.

    Article  CAS  PubMed  Google Scholar 

  91. de Graaff E, Maat P, Hulsenboom E, van den Berg R, van den Bent M, Demmers J, et al. Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. Ann Neurol. 2012;71:815–24.

    Article  PubMed  CAS  Google Scholar 

  92. Graus F, Gultekin SH, Ferrer I, Reiriz J, Alberch J, Dalmau J. Localization of the neuronal antigen recognized by anti-Tr antibodies from patients with paraneoplastifc cerebellar degeneration and Hodgkin’s disease in the rat nervous system. Acta Neuropathol. 1998;96(1):1–7.

    Article  CAS  PubMed  Google Scholar 

  93. Geschwind MD, Tan KM, Lennon VA, Barajas RF Jr, Haman A, Klein CJ, et al. Voltage-gated potassium channel autoimmunity mimicking creutzfeldt-jakob disease. Arch Neurol. 2008;65(10):1341–6.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Flanagan EP, Kotsenas AL, Britton JW, McKeon A, Watson RE, Klein CJ, et al. Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures. Neurol Neuroimmunol Neuroinflamm. 2015;2(6):e161.

    Article  PubMed  PubMed Central  Google Scholar 

  95. Dalmau J, Graus F, Villarejo A, Posner JB, Blumenthal D, Thiessen B, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain J Neurol. 2004;127(Pt 8):1831–44.

    Article  Google Scholar 

  96. Flanagan EP, McKeon A, Lennon VA, Kearns J, Weinshenker BG, Krecke KN, et al. Paraneoplastic isolated myelopathy: clinical course and neuroimaging clues. Neurology. 2011;76(24):2089–95.

    Article  CAS  PubMed  Google Scholar 

  97. Toledano M, Britton JW, McKeon A, Shin C, Lennon VA, Quek AM, et al. Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology. 2014;82(18):1578–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Graus F, Vincent A, Pozo-Rosich P, Sabater L, Saiz A, Lang B, et al. Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes. J Neuroimmunol. 2005;165(1–2):166–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Vitaliani R, Mason W, Ances B, Zwerdling T, Jiang Z, Dalmau J. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratomas. Ann Neurol. 2005;58(4):594–604.

    Article  PubMed  PubMed Central  Google Scholar 

  100. Quek AM, Britton JW, McKeon A, So E, Lennon VA, Shin C, et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t.]. 2012;69(5):582–93.

    Google Scholar 

  101. Irani SR, Michell AW, Lang B, Pettingill P, Waters P, Johnson MR, et al. Faciobrachial dystonic seizures precede LGI1 antibody limbic encephalitis. Ann Neurol. 2011;69(5):892–900.

    Article  PubMed  Google Scholar 

  102. McKeon A, Lennon VA, Pittock SJ. Immunotherapy-responsive dementias and encephalopathies. Continuum (Minneap Minn). 2010;16(2 Dementia):80–101.

    Google Scholar 

  103. Flanagan EP, McKeon A, Lennon VA, Boeve BF, Trenerry MR, Tan KM, et al. Autoimmune dementia: clinical course and predictors of immunotherapy response. Mayo Clin Proc. 2010;85(10):881–97.

    Article  PubMed  PubMed Central  Google Scholar 

  104. O’Toole O, Lennon VA, Ahlskog JE, Matsumoto JY, Pittock SJ, Bower J, et al. Autoimmune chorea in adults. Neurology. 2013;80(12):1133–44.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  105. Panzer J, Dalmau J. Movement disorders in paraneoplastic and autoimmune disease. Curr Opin Neurol. D - 9319162. 2011;24(4):346–353.

    Article  PubMed  PubMed Central  Google Scholar 

  106. Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain J Neurol. 2000;123(Pt 7):1481–94.

    Article  Google Scholar 

  107. McKeon A, Robinson MT, McEvoy KM, Matsumoto JY, Lennon VA, Ahlskog JE, et al. Stiff-man syndrome and variants: clinical course, treatments, and outcomes. Arch Neurol. 2012;69(2):230–8.

    Article  PubMed  Google Scholar 

  108. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med. 2003;349(16):1543–54.

    Article  CAS  PubMed  Google Scholar 

  109. Lundh H, Nilsson O, Rosen I, Johansson S. Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome. Acta Neurol Scand. 1993;88(2):136–40.

    Article  CAS  PubMed  Google Scholar 

  110. Hart IK, Maddison P, Newsom-Davis J, Vincent A, Mills KR. Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain J Neurol. 2002;125(Pt 8):1887–95.

    Article  Google Scholar 

  111. Rudnicki SA, Dalmau J. Paraneoplastic syndromes of the spinal cord, nerve, and muscle. Muscle Nerve. 2000;23(12):1800–18.

    Article  CAS  PubMed  Google Scholar 

  112. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase musk in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. D – 9502015. 2001;7(3):365–368.

    Article  CAS  PubMed  Google Scholar 

  113. Evoli A, Tonali PA, Padua L, Monaco ML, Scuderi F, Batocchi AP, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain J Neurol. 2003;126:2304–11.

    Article  Google Scholar 

  114. Lambert EH, Lennon VA. Selected IgG rapidly induces Lambert-Eaton myasthenic syndrome in mice: complement independence and EMG abnormalities. Muscle Nerve. 1988;11:1133–45.

    Article  CAS  PubMed  Google Scholar 

  115. Mammen AL. Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol. 2011;7(- 1759-4766 (Electronic)):343–54.

    Article  CAS  PubMed  Google Scholar 

  116. Dalakas MC. Immunopathogenesis of inflammatory myopathies. Ann Neurol. 1995;37(Suppl 1):S74–86.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Mayo Clinic, Rochester, MN, USA

    Nicholas L. Zalewski

  2. Department of Neurology, Mayo Clinic’s Center for Multiple Sclerosis and Autoimmune Neurology and of Mayo’s Neuroimmunology Research Laboratory, Rochester, MN, USA

    Sean J. Pittock

Authors
  1. Nicholas L. Zalewski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sean J. Pittock
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sean J. Pittock .

Editor information

Editors and Affiliations

  1. Division of Neuroimmunology, University of Iowa, Iowa City, IA, USA

    Tracey A. Cho

  2. Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Shamik Bhattacharyya

  3. Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Simon Helfgott

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Zalewski, N.L., Pittock, S.J. (2019). Paraneoplastic Neurologic Disease. In: Cho, T., Bhattacharyya, S., Helfgott, S. (eds) Neurorheumatology. Springer, Cham. https://doi.org/10.1007/978-3-030-16928-2_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-16928-2_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-16927-5

  • Online ISBN: 978-3-030-16928-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation